跳至主要内容
临床试验/ACTRN12610000323022
ACTRN12610000323022尚未招募未知

Intrathecal baclofen therapy for management of spasticity: An Australian paediatric multicentre prospective audit.

Princess Margaret Hospital for Children0 个研究点目标入组 100 人开始时间: 2010年4月21日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
o limit 至 18 Years(—)
性别
All

入选标准

  • Enrolment in this paediatric long term outcome audit will be offered to new patients offered ITB therapy.
  • The decision whom is offered ITB therapy in Western Australia rests with Movement Disorder’s team at Princess Margaret Hospital. This decision is made following a multidisciplinary medical assessment process including a test dose of intrathecal baclofen.
  • Hospitals providing paediatric ITB programmes in Australia include Princess Margaret Hospital for Children (Perth), Royal Childrens Hospital (Melbourne), Monash Medical Centre (Melbourne), Westmead Childrens Hospital (Sydney), Women & Childrens Hospital (Adelaide) and the Royal Childrens Hospital (Brisbane).

排除标准

  • There are no specific exclusion criteria.

研究者

发起方
Princess Margaret Hospital for Children

相似试验